Skip to main content
  • FOR PATIENTS

bayer logo

ATTENTION

The information on this page is intended for healthcare professionals in the United States and is not intended for the general public.

I AM A HEALTHCARE PROFESSIONAL

I AM NOT A HEALTHCARE PROFESSIONAL

  • CONTACT US
Bayer® Aspirin logo
  • EFFICACY AND SAFETY
  • HEART HEALTH TOOLS & RESOURCES
  • INDICATIONS AND DOSING
Bayer Cross Logo
  1. Home
  2. Resource Library

HEART HEALTH TOOLS & RESOURCES 

Welcome to the Bayer® Aspirin Heart Health Resource Center

Here you’ll find a number of items, including our new Bayer® Aspirin Heart Risk Assessment quiz for patients, to help you have a meaningful discussion with your patients about their cardiovascular (CV) risk factors.

Bayer red circle icon of two people standing

Patient Education

(CV Risk Awareness and More)

Bayer red circle icon of two people communicating in a discussion

Patient Discussion

(Secondary Prevention)

Bayer red circle icon of a book

Relevant Publications

(Journal Articles, Guidelines, and More)

Bayer red circle icon of a person on a computer monitor speaking

Practice Education

(Videos and More)

Patient Education

(CV Risk Awareness and More)

screen shot of Bayer aspirin website or app showing shield icon with Bayer logo stating offical sponsor of fan's hearts with heart at the bottom and headline of take a timeout for your heart - get started

15 questions are split into 4 categories— “Getting to Know You,” “Your Body,” “Your Lifestyle,” and “Health & History” 

screen shot of Bayer aspirin website or app showing health risk assessment questionaire quiz  asking how often do you watch sports content

The “Getting to Know You” questions ask patients for their age, as well as their habits surrounding sports.

screen shot of Bayer aspirin website or app showing health risk assessment questionaire quiz  asking what is your resting heart rate

The “Your Body” questions are intended to collect basic demographic information—including resting heart rate and sex assigned at birth. 

screen shot of Bayer aspirin website or app showing health risk assessment questionaire quiz  asking about how many hours of sleep do you usually get in 24 hours

The “Your Lifestyle” questions assess behavioral habits that could play a role in the development of CVD (including sleep routines and alcohol consumption).

screen shot of Bayer aspirin website or app showing health risk assessment questionaire quiz  asking about how many hours of sleep do you usually get in 24 hours

The “Your Lifestyle” questions assess behavioral habits that could play a role in the development of CVD (including sleep routines and alcohol consumption).

screen shot of Bayer aspirin website or app showing health risk assessment questionaire quiz asking have you been diagnosed with any of the following conditions

The “Health & History” questions take into account certain relevant existing conditions a patient may have, as well as any family history of CVD or related conditions.

screen shot of Bayer aspirin website or app showing health risk assessment questionaire quiz asking do any of your close relatives have a heart disease

The “Health & History” questions take into account certain relevant existing conditions a patient may have, as well as any family history of CVD or related conditions.

screen shot of Bayer aspirin website or app showing health risk assessment questionaire quiz results page

Their answers produce risk assessment results, which tell patients whether they are at lower, average, or higher risk of developing CVD over the next 10 years.† Once they have their results, patients should contact their HCP to help inform your evaluation before any next steps are taken.

screen shot of Bayer aspirin website or app showing health risk assessment questionaire quiz results page with details of diagnosis

The results can be viewed in detail, including what they’re doing well and potential risk factors.

NEW! Bayer® Aspirin Heart Risk Assessment—a valuable tool for patient education about awareness of CV risk factors 

  • An evidence-based patient self-assessment
  • Created and informed by expert cardiologists, this reflects well-established risk factors*
  • Can help patients understand their potential risk factors for cardiovascular disease (CVD)
  • Asks 15 questions and educates patients on whether they are lower, average, or higher risk† based on their risk factors over a 10-year period
  • Allows patients to be more prepared for your conversations

*This assessment, developed by Huma Therapeutics (“HUMA”) and Bayer, is based on data from 466,052 participants in the United Kingdom recruited from 2006 to 2010. It estimates a patient’s 10-year risk of CVD by comparing their answers with the research population. The research is published in the European Heart Journal—Digital Health. Patients are informed that the assessment does not replace an assessment by a qualified healthcare professional.  
†Compared with the population researched.1

Some questions your patients may ask you after using the tool include:

  • What is my risk for a heart attack or stroke?
  • What are the warning signs or symptoms I should watch out for?
  • What can I do to lower my risk of heart disease and stroke?
  • What is my blood pressure? Is it at a healthy level?
  • What is my blood cholesterol? Is it at a healthy level?
  • What is my blood sugar? Is it at a healthy level?
  • What is a heart healthy exercise plan for me?
  • What is a heart healthy eating plan for me?
  • Are there any nutritional supplements that would help support my heart health?

EXPLORE THE BAYER®ASPIRIN HEART RISK ASSESSMENT

Patient Discussion

(Secondary Prevention)

patient brochure

Patient Brochure

This is a patient-friendly tool for counseling people who've had an MI or ischemic stroke on the importance of complying with a secondary prevention regimen with Bayer® Aspirin.

DOWNLOAD

Relevant Publications

(Journal Articles, Guidelines, and More)

guidelines

Clinical Practice Guidelines

Clinical practice guidelines continue to recommend aspirin as a top-tier, first-line treatment option for secondary CV event prevention.2-9

DOWNLOAD
secondary prevention

Secondary Prevention Editorial

This is an evidence-based editorial discussing the role and benefit-to-risk profile of low-dose aspirin in the prevention of secondary CV events.

DOWNLOAD
papework of a cardio risk assessment study

Digital Cardiovascular Risk Assessment Study

HUMA developed a risk assessment tool based on data from 400,000+ participants, published in the European Heart Journal—Digital Health.1

VIEW ARTICLE
clinicalReprint ATT

ATT Collaboration

The Antithrombotic Trialists’ (ATT) Collaboration meta-analysis of randomized trials of aspirin in the prevention of vascular disease concluded that aspirin can reduce the risk of a second MI by 31%.10

VIEW ARTICLE
clinical Reprint-saini

PPI Co-therapy

See how proton pump inhibitor co-therapy with aspirin could help reduce both GI and CV events in patients with CHD, making it a cost-effective approach.11

VIEW ARTICLE
Adaptable aspirin study

Adaptable Trial

The Adaptable Study concluded that a daily dose of aspirin 81 mg had efficacy and safety comparable to aspirin 325 mg in secondary CV prevention.12

VIEW ARTICLE

Practice Education

(Videos and More)

screen showing a video ready to play heart health education

Bayer Low Dose Safety Coated 81 mg Aspirin may help improve GI tolerability

References: 1. Dolezalova N, Reed AB, Despotovic A, et al. Development of an accessible 10-year digital cardiovascular (DiCAVA) risk assessment: a UK Biobank study. Eur Heart J. 2021;2(3):528-538. doi:10.1093/ehjdh/ztab057 2. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non–ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;64(24):e139-e228. doi:10.1016/j.jacc.2014.09.017 3. O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61(4):e78-e140. doi:10.1016/j.jacc.2012.11.019 4. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease. J Am Coll Cardiol. 2012;60(24):e44-e164. doi:10.1016/j.jacc.2012.07.013 5. Kulik A, Ruel M, Jneid H, et al. Secondary prevention after coronary artery bypass graft surgery: a scientific statement from the American Heart Association. Circulation. 2015;131(10):927-964. doi:10.1161/CIR.0000000000000182 6. Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease. Circulation. 2016;134(10):e123-e155. doi:10.1161/CIR.0000000000000404​​​​​​​ 7. Brott TG, Halperin JL, Abbara S, et al. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: executive summary. Circulation. 2011;124(4):489-532. doi:10.1161/CIR.0b013e31820d8d78 8. Bushnell C, McCullough LD, Awad IA, et al. Guidelines for the prevention of stroke in women: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(5):1545-1588. doi:10.1161/01.str.0000442009.06663.48  9. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(7):2160-2236. doi:10.1161/STR.0000000000000024​​​​​​​ 10. Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849-1860. doi:10.1016/S0140-6736(09)60503-1​​​​​​​ 11. Saini SD, Fendrick AM, Scheiman JM. Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention. Aliment Pharmacol Ther. 2011;34(2):243-251. doi:10.1111/j.1365-2036.2011.04707.x​​​​​​​ 12. Jones WS, Mulder H, Wruck LM, et al. Comparative effectiveness of aspirin dosing in cardiovascular disease. N Engl J Med. 2021;384(21):1981-1990. doi:10.1056/NEJMoa2102137

Bayer® Aspirin logo
  • EFFICACY AND SAFETY
  • HEART HEALTH TOOLS & RESOURCES
  • INDICATIONS AND DOSING

©2023. All rights reserved. Unless otherwise indicated, all trademarks are owned by Bayer, and its affiliates, or licensed for its use.

USE AS DIRECTED.

  • Bayer Global
  • Bayer US
  • Bayer Consumer Health
  • Conditions of Use
  • Privacy Statement
  • Imprint
  • California Transparency in Supply Chains
  • Satisfaction Guarantee
  • AdChoices
  • Do not sell or share my Personal Data
  • Accessibility

Level Access website accessibility icon